Clinigen Group extends agreement to exclusively supply clinical trials with Accord Healthcare’s EU Oncology Products

Burton-on-Trent, UK – 20 June 2013 - Clinigen Group plc (‘Clinigen’ or the ‘Group’) (AIM: CLIN) today announced that Clinigen Clinical Trial Supply (‘CTS’) has extended its exclusive clinical trial distribution agreement with Accord Healthcare (‘Accord’), to supply clinical trials with Accord’s European injectable oncology drug portfolio for a further two years.

Under the terms of the extended agreement, CTS will continue to distribute Accord’s EU portfolio of more than 15 injectable oncology drugs including cisplatin, cytarabine, doxorubicin and fluorouracil to manufacturers, CROs, clinical re-packagers, and other specialist providers for use in clinical trials. CTS will remain the sole point of contact for all clinical trial supply enquiries and orders.

“The quality and efficiency of Clingen’s services has been excellent and therefore, we are keen to renew our distribution agreement,” said Daniel Green, Hospital Director UK & Ireland at Accord. “Faced with an increasing demand for our products, the Clinigen team has ensured a seamless, controlled management of our injectable oncology portfolio. This has resulted in improved access to our products and a level of support to our customers that we were previously unable to provide.”

Shaun Chilton, Chief Operating Officer, Clinigen Group said, “We look forward to the continuation of our partnership with Accord and are pleased that they have chosen to extend our agreement. It is testament to the successful combination of Accord’s international manufacturing capabilities and Clinigen’s expertise in managing the increasingly complex challenges in clinical trials supply. As a Group we are able to provide both the resources and insight into our clients’ needs. This allows us to offer the highest level of service on a global scale.”

- Ends -

About Clinigen Group
Clinigen is a specialty global pharmaceutical company headquartered in the UK, with offices in the US and Japan. The Group has three operating businesses; Specialty Pharmaceuticals (SP), Clinical Trials Supply (Clinigen CTS), and Global Access Programs (Clinigen GAP). Clinigen CTS sources commercial medical products for use in clinical studies. These include comparator drugs, where existing medical treatments are used as benchmarks to assess the effectiveness of investigative products, adjuvant drugs, which improve the effectiveness of the product being trialed, and rescue therapies, which help patients who have experienced a worsening of symptoms or insufficient therapeutic benefit during a trial. For more information, please visit

About Accord Healthcare
Accord is a global company with a presence in Australia, Brazil, Canada, Kenya, Mexico, New Zealand, Peru, South Africa, Spain, the UK, the US and Vietnam. Accord is committed to maximizing customer satisfaction by introducing innovative, quality products to the market. For more information, please visit

Contact Details

Clinigen Group plc

Tel: +44 (0) 1283 495 010

Peter George, Group Chief Executive Officer

Shaun Chilton, Chief Operating Officer


College Hill (media relations)

Tel: +44 (0) 20 7457 2020

Melanie Toyne-Sewell/Stefanie Bacher/Jen Lewis

Email: [email protected]